# Frequently asked, plainly answered > FAQ — Skin & Aesthetics Research Peptides — peptidebarbie — Direct, cited answers to the most-asked questions about Skin & Aesthetics research peptides: what GLOW contains, what GHK-Cu actually does, whether it is genuinely anti-aging, and how Melanotan II works. **SKIN & AESTHETICS / QUESTIONS** Twelve questions people actually type, answered from the cited literature — including the ones where the honest answer is that nobody has measured it. ## What is GLOW peptide? GLOW is not a single peptide at all — it is a co-formulated vial containing three separate research peptides, most commonly GHK-Cu, BPC-157 and TB-500. It is sold by research suppliers and mixed by clinics rather than manufactured to any approved standard, so ratios and purity vary by source. No controlled clinical trial of the GLOW combination exists for any purpose; every claim made for it is extrapolated from research on its individual ingredients plus a mechanistic argument for why they might work well together [1]. ## What does the GLOW peptide do? In theory, the three ingredients cover a repair process from three angles: GHK-Cu prompts skin cells to build collagen, elastin and other structural material [4][5]; BPC-157 promotes new blood-vessel growth through VEGFR2 signalling [3]; and the thymosin beta-4 fragment promotes cell migration into damaged tissue [7]. In practice, what the blend does in a human being has never been measured. A 2026 review naming all three constituents concluded that unapproved peptides of this class show favourable tissue-repair outcomes in animal models while rigorous human safety data remain scarce and the potential for serious harm is real [1]. ## What does GLOW peptide have in it? Three peptides in one vial: a copper-carrying tripeptide, a synthetic gastric-derived pentadecapeptide, and a seven-amino-acid fragment of a natural repair protein. What is *not* in it is a standard — the milligram ratios published by suppliers differ between sources and have no basis in any controlled human trial. That non-standardisation is a substantive problem, not a footnote: combination pharmacokinetics, interaction effects and the stability of co-formulating a copper complex alongside two other peptides have not been studied for this blend at all. ## What peptides are in the GLOW blend? **GHK-Cu** — the copper(II) complex of glycyl-L-histidyl-L-lysine, a matrix-remodeling peptide and, as topical Copper Tripeptide-1, a legal cosmetic ingredient [4]. **BPC-157** — a synthetic stable pentadecapeptide derived from a gastric body-protection protein, an unapproved research chemical that a 2025 review found had been examined in only three small human pilot studies and should be considered investigational [2]. **TB-500** — an acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 [7]. Both BPC-157 and TB-500 are prohibited in sport at all times. ## What does a GHK-Cu peptide do? GHK-Cu carries copper into tissue and signals dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the matrix metalloproteinases that break those structures down [4][5]. In topical human studies that translates into measurable, modest changes: a 2025 review reports procollagen synthesis increased in 70% of GHK-Cu-treated subjects against 50% for vitamin C and 40% for retinoic acid, alongside placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [8]. It also has a documented effect on hair-follicle cells. ## What is GHK-Cu and how does it work? GHK-Cu is a three-amino-acid peptide — glycine, histidine, lysine — bound one-to-one to a copper(II) ion. The peptide sequence occurs naturally inside type I collagen, and free GHK circulates in plasma at levels that decline with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60 [4]. It works as both a copper chaperone, supplying the copper that lysyl oxidase needs to cross-link collagen and elastin, and as a direct signal to fibroblasts and keratinocytes at picomolar-to-nanomolar concentrations [5]. ## Is GHK-Cu peptide really anti-aging? Partly, within narrow limits, and less dramatically than advertised. The controlled human evidence is small topical dermatology studies showing improvements in laxity, clarity, fine lines and wrinkle depth [4][8], plus one 45-man hair trial of a combination formulation rather than the peptide alone [10]. The sweeping claims come from elsewhere: GHK modulates expression of about 31.2% of human genes at a 50%-or-greater change threshold [9], but that finding derives largely from database analyses awaiting protein-level validation, much of the foundational literature comes from a single research group, and the popular "4,000 genes" figure is an extrapolation from broader thresholds. ## What is the difference between GHK and GHK-Cu? GHK is the bare tripeptide; GHK-Cu is that tripeptide holding a copper(II) ion. The distinction is not cosmetic, and the literature conflates the two constantly. Most of the documented tissue-remodeling activity depends on the copper actually being coordinated — the free peptide without copper fails to reproduce key effects such as MMP-2 stimulation in cell studies. Intact binding also matters for safety: the complex holds copper with a high stability constant, which prevents it from acting as a loose pro-oxidant, so a degraded or destabilised product is not equivalent [8]. ## What is Melanotan 2? Melanotan II is a synthetic cyclic seven-amino-acid analog of alpha-melanocyte-stimulating hormone, designed in the late 1980s at the University of Arizona to be far more potent and far more resistant to enzymatic breakdown than the natural hormone. It activates the melanocortin receptors non-selectively, MC1R through MC5R. It has never been approved by any regulator for any indication, and no Phase II or Phase III trial of it was ever completed [15]. Regulators including the FDA, TGA, MHRA and HPRA have issued warnings about melanotan products. ## What is Melanotan 2 used for in research? Its documented clinical testing was for male erectile dysfunction. In a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction, subcutaneous melanotan II at 0.025 mg/kg produced clinically apparent erections in 8 of 10, with mean duration of greater-than-80% tip rigidity of 38.0 minutes against 3.0 minutes on placebo [16]. In animal research it is used as a melanocortin agonist probe — for example microinjected into the mouse nucleus accumbens at 0.1 to 1 nmol per side to study appetite and food motivation [13]. Recent human literature is predominantly case reports of adverse events [12][14]. ## How does Melanotan 2 work in the body? It binds and activates all five melanocortin receptors rather than selecting one, which is why its effects reach so far beyond pigment. At MC1R on melanocytes it triggers pigment synthesis without ultraviolet exposure. At MC4R and MC3R in the hypothalamus and mesolimbic system it suppresses appetite and drives pro-erectile and sexual-motivation effects [13][16]. At MC5R it touches exocrine and sebaceous gland function. Because a single molecule addresses the whole receptor family, appetite loss, nausea, flushing, spontaneous erections and blood-pressure effects are not stray side effects — they are the same signal. ## What is the melanogenesis (MC1R-cAMP-MITF) signaling cascade? It is the chain of events that turns a receptor signal into visible pigment. When MC1R on a melanocyte is activated, intracellular cAMP rises, which activates protein kinase A, which phosphorylates the transcription factor CREB, which in turn drives expression of MITF — the master regulator of the pigment-cell programme. MITF upregulates tyrosinase, the rate-limiting enzyme of melanin synthesis, shifting production toward eumelanin, the darker pigment. Ultraviolet light normally initiates this cascade indirectly; a melanocortin agonist starts it at the receptor, skipping the sunlight [15]. --- An independent reading desk for the skin, hair and pigmentation peptide literature, where every enthusiastic sentence arrives with a citation and a caveat attached — not a clinic, not a vendor, not a prescription.